ROMosozumab early experience in female patients with severe osteoporosis in an Italian real-world setting, the ROMEO study.

ABSTRACT: The impact of romosozumab on the bone mineral density surrogate threshold effect (BMD-STE) in postmenopausal women with severe osteoporosis is unknown. Significant BMD gains with romosozumab were observed and 60% of patients achieved the BMD-STE at month 12, regardless of bisphosphonate pre-exposure. Romosozumab offers effective treatment in high-risk fracture patients.

Purpose

A real-life study to investigate the impact of romosozumab on the bone mineral density surrogate threshold effect (BMD-STE) for minimal fracture risk reduction.  METHODS: A retrospective analysis of postmenopausal women with severe osteoporosis newly treated with romosozumab from 29 November 2022 until 01 July 2024 (extraction date). BMD of the lumbar spine (L1-L4), femoral neck, and total hip was assessed at

SUBMITTER: Adami G 

PROVIDER: S-EPMC12672652 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature